Scholar Rock Demonstrates that Highly Specific TGFβ1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade Therapy

World News: . []

CAMBRIDGE Mass Nov 09 2018 GLOBE NEWSWIRE -- Holding Corporation NASDAQSRRK a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which play a fundamental role today announced new preclinical data from i...

More news and information about Scholar Rock

Published By:

Globe Newswire: 13:00 GMT Friday 9th November 2018

Published: .

Search for other references to "scholar" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us